HIV-Associated Cancers: Module

CE / CME

Managing Increased Cancer Risk in Transgender Individuals With HIV Infection

Pharmacists: 0.75 contact hour (0.075 CEUs)

Nurses: 0.75 Nursing contact hour, including 0.75 hour of pharmacotherapy credit 

Physicians: Maximum of 0.75 AMA PRA Category 1 Credit

Released: November 07, 2022

Expiration: November 06, 2023

Ariela Noy
Ariela Noy, MD

Activity

Progress
1
Course Completed
References

  1. CDC. HIV and transgender people. cdc.gov/hiv/group/gender/transgender/index.html. Accessed October 27, 2022.
  2. Stutterheim SE, van Dijk M, Wang H, et al. The worldwide burden of HIV in transgender individuals: an updated systematic review and meta-analysis. PLoS One. 2021;16:e0260063.
  3. WHO. HIV. who.int/data/gho/data/themes/hiv-aids. Accessed October 27, 2022.
  4. Grant JM, Mottet LA, Tanis J, et al. Injustice at every turn: a report of the national transgender discrimination survey. Washington, DC: National Center for Transgender Equality and National Gay and Lesbian Task Force; 2011.
  5. CDC. HIV risk among persons who exchange sex for money or nonmonetary items. cdc.gov/hiv/group/sexworkers.html. Accessed October 27, 2022.
  6. Yuan T, Hu Y, Zhou X, et al. Incidence and mortality of non-AIDS-defining cancers among people living with HIV: a systematic review and meta-analysis. 2022;52:101613.
  7. Cobucci RNO, Lima PH, de Souza PC, et al. Assessing the impact of HAART on the incidence of defining and non-defining AIDS cancers among patients with HIV/AIDS: a systematic review. J Infect Public Health. 2015;8:1-10.
  8. Silverberg MJ, Neuhaus J, Bower M, et al. Risk of cancers during interrupted antiretroviral therapy in the SMART study. AIDS. 2007;21:1957-1963.
  9. Eng C, Ciombor KK, Cho M, et al. Anal cancer: emerging standards in a rare disease. J Clin Oncol. 2022;40:2774-2788.
  10. Cunningham CO, Doran B, DeLuca J, et al. Routine opt-out HIV testing in an urban community health center. AIDS Patient Care STDS. 2009;23:619-623.
  11. Jackson SS, Han X, Mao Z, et al. Cancer stage, treatment, and survival among transgender patients in the United States. J Natl Cancer Inst. 2021;113:1221-1227.
  12. National Cancer Institute. HIV infection and cancer risk. cancer.gov/about-cancer/causes-prevention/risk/infectious-agents/hiv-fact-sheet. Accessed October 27, 2022.
  13. Berhan A, Bayleyegn B, Getaneh Z. HIV/AIDS associated lymphoma: review. Blood Lymphat Cancer. 2022;12:31-45.
  14. Hernández-Ramírez RU, Shiels MS, Dubrow R, et al. Cancer risk in HIV-infected people in the USA from 1996 to 2012: a population-based, registry-linkage study. Lancet HIV. 2017;4:e495-e504.
  15. Silverberg MJ, Lau B, Achenbach CJ, et al. Cumulative incidence of cancer among persons with HIV in North America: a cohort study. Ann Intern Med. 2015;163:507-518.
  16. American Cancer Society. Types of B-cell lymphoma. cancer.org/cancer/non-hodgkin-lymphoma/about/b-cell-lymphoma.html. Accessed October 27, 2022.
  17. Barta SK, Xue X, Wang D, et al. Treatment factors affecting outcomes in HIV-associated non-Hodgkin lymphomas: a pooled analysis of 1546 patients. Blood. 2013;122:3251-3262.
  18. Bartlett NL, Wilson WH, Jung SH, et al. Dose-adjusted EPOCH-R compared with R-CHOP as frontline therapy for diffuse large B-cell lymphoma: clinical outcomes of the phase III Intergroup Trial Alliance/CALGB 50303. J Clin Oncol. 2019;37:1790-1799.
  19. National Comprehensive Cancer Network. Clinical practice guidelines in oncology: B-cell lymphomas. v.5.2022. nccn.org. Accessed October 27, 2022.
  20. Roschewski M, Dunleavy K, Abramson JS, et al. Multicenter study of risk-adapted therapy with dose-adjusted EPOCH-R in adults with untreated Burkitt lymphoma. J Clin Oncol. 2020;38:2519-2529.
  21. Sparano JA, Lee JY, Kaplan LD, et al. Rituximab plus concurrent infusional EPOCH chemotherapy is highly effective in HIV-associated B-cell non-Hodgkin lymphoma. Blood. 2010;115:3008-3016.
  22. Schommers P, Gillor D, Hentrich M, et al. Incidence and risk factors for relapses in HIV-associated non-Hodgkin lymphoma as observed in the German HIV-related lymphoma cohort study. Haematologica. 2018;103:857-864.
  23. Mounier N, Spina M, Gabarre J, et al. AIDS-related non-Hodgkin lymphoma: final analysis of 485 patients treated with risk-adapted intensive chemotherapy. Blood. 2006;107:3832-3840.
  24. Ramos JC, Sparano JA, Chadburn A, et al. Impact of Myc in HIV-associated non-Hodgkin lymphomas treated with EPOCH and outcomes with vorinostat (AMC-075 trial). Blood. 2020;136:1284-1297.
  25. Levine AM, Li P, Cheung T, et al. Chemotherapy consisting of doxorubicin, bleomycin, vinblastine, and dacarbazine with granulocyte-colony-stimulating factor in HIV-infected patients with newly diagnosed Hodgkin's disease: a prospective, multi-institutional AIDS clinical trials group study (ACTG 149). J Acquir Immune Defic Syndr. 2000;24:444-450.
  26. Montoto S, Shaw K, Okosun J, et al. HIV status does not impact on outcome in patients with Hodgkin lymphoma treated with ABVD chemotherapy in the HAART era. Presented at: 2011 American Society of Hematology Annual Meeting and Exposition; December 10-13, 2011. Abstract 3646.
  27. Hentrich M, Berger M, Wyen C, et al. Stage-adapted treatment of HIV-associated Hodgkin lymphoma: results of a prospective multicenter study. J Clin Oncol. 2012;30:4117-4123.
  28. National Comprehensive Cancer Network. Clinical practice guidelines in oncology: cancer in people with HIV. v.1.2022. nccn.org. Accessed October 27, 2022.
  29. Rubinstein PG, Moore PC, Bimali M, et al. Safety and efficacy of brentuximab vedotin in combination with AVD in stage II-IV HIV-associated classical Hodgkin lymphoma: results of the phase 2 study, AMC 085. Presented at: 2019 American Society of Hematology Annual Meeting and Exposition; December 7-10, 2019. Abstract 130.
  30. Horwitz S, O’Connor OA, Pro B, et al. Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial. Lancet. 2019;393:229-240.
  31. Re A, Michieli M, Casari S, et al. High-dose therapy and autologous peripheral blood stem cell transplantation as salvage treatment for AIDS-related lymphoma: long-term results of the Italian Cooperative Group on AIDS and Tumors (GICAT) study with analysis of prognostic factors. Blood. 2009;114:1306-1313.
  32. Sahin IH, Kane SR, Brutcher E, et al. Safety and efficacy of immune checkpoint inhibitors in patients with cancer living with HIV: a perspective on recent progress and future needs. JCO Oncol Pract. 2020;16:319-325.
  33. Schneider JW, Dittmer DP. Diagnosis and treatment of Kaposi sarcoma. Am J Clin Dermatol. 2017;18:529-539.
  34. Cesarman E, Damania B, Krown SE, et al. Kaposi sarcoma. Nat Rev Dis Primers. 2019;5:9.
  35. Cavallin LE, Goldschmidt-Clermont P, Mesri EA. Molecular and cellular mechanisms of KSHV oncogenesis of Kaposi's sarcoma associated with HIV/AIDS. PLoS Pathog. 2014;10:e1004154.
  36. Semango GP, Charles RM, Swai CI, et al. Prevalence and associated risk factors for Kaposi's sarcoma among HIV-positive patients in a referral hospital in Northern Tanzania: a retrospective hospital-based study. BMC Cancer. 2018;18:1258.
  37. Quinlivan EB, Zhang C, Stewart PW, et al. Elevated virus loads of Kaposi’s sarcoma-associated human herpesvirus 8 predict Kaposi’s sarcoma disease progression, but elevated levels of human immunodeficiency virus type 1 do not. J Infect Dis. 2002;185:1736-1744.
  38. Baldini F, Baiocchini A, Schininà V, et al. Brain localization of Kaposi’s sarcoma in a patient treated by combination antiretroviral therapy. BMC Infect Dis. 2013;13:600.
  39. Nasti G, Talamini R, Antinori A, et al. AIDS-related Kaposi’s sarcoma: evaluation of potential new prognostic factors and assessment of the AIDS Clinical Trial Group Staging System in the Haart Era—the Italian Cooperative Group on AIDS and Tumors and the Italian Cohort of Patients Naive From Antiretrovirals. J Clin Oncol. 2003;21:2876-2882. 
  40. National Comprehensive Cancer Network. Clinical practice guidelines in oncology: Kaposi sarcoma. v.1.2022. nccn.org. Accessed October 27, 2022.
  41. Bansal A, Singh MP, Rai B. Human papillomavirus-associated cancers: a growing global problem. Int J Appl Basic Med Res. 2016;6:84-89.
  42. Liu G, Sharma M, Tan N, et al. HIV-positive women have higher risk of human papilloma virus infection, precancerous lesions, and cervical cancer. AIDS. 2018;32:795-808.
  43. University of California, San Francisco Transgender Care. Guidelines for the primary and gender-affirming care of transgender and gender nonbinary people. transcare.ucsf.edu/guidelines. Accessed October 27, 2022.
  44. Clifford GM, Georges D, Shiels MS, et al. A meta-analysis of anal cancer incidence by risk group: toward a unified anal cancer risk scale. Int J Cancer. 2021;148:38-47.
  45. Braun H, Nash R, Tangpricha V, et al. Cancer in transgender people: evidence and methodological considerations. Epidemiol Rev. 2017;39:93-107.
  46. Yang DX, Soulos PR, Davis B, et al. Impact of widespread cervical cancer screening: number of cancers prevented and changes in race-specific incidence. Am J Clin Oncol. 2018;41:289-294.
  47. Darragh TM, Winkler B. Anal cancer and cervical cancer screening: key differences. Cancer Cytopathol. 2011;119:5-19.
  48. Palefsky JM, Lee JY, Jay N, et al. Treatment of anal high-grade squamous intraepithelial lesions to prevent anal cancer. N Engl J Med. 2022;386:2273-2282.
  49. New York State Department of Health AIDS Institute. Screening for anal dysplasia and cancer in adults with HIV. hivguidelines.org/hiv-care/anal-cancer/. Accessed October 27, 2022.
  50. Palefsky JM, Giuliano AR, Goldstone S, et al. HPV vaccine against anal HPV infection and anal intraepithelial neoplasia. N Engl J Med. 2011;365:1576-1585.
  51. Johnston PI, Wright SW, Orr M, et al. Worldwide relative smoking prevalence among people living with and without HIV. AIDS. 2021;35:957-970.
  52. Cadranel J, Garfield D, Lavolé A, et al. Lung cancer in HIV infected patients: facts, questions and challenges. Thorax. 2006;61:1000-1008.
  53. Uldrick TS, Ison G, Rudek MA, et al. Modernizing clinical trial eligibility criteria: recommendations of the American Society of Clinical Oncology-Friends of Cancer Research HIV Working Group. J Clin Oncol. 2017;35:3774-3780.